Patients are at the center of everything we do at GlycoMimetics and we are deeply grateful to the people living with life-threatening diseases who consent to participate in clinical research to advance our understanding of potential medicines in development. Through collaboration with our clinical partners, our goal is to develop medicines that extend and improve the lives of patients. We do this through the conduct of high-quality clinical research designed to provide regulatory authorities with the robust data required for review and approval.
Ongoing Trials
Uproleselan (GMI-1271) is being evaluated by the National Cancer Institute in two studies:
- As a potential new treatment for newly diagnosed AML patients fit for chemotherapy (NCT03701308). Enrollment in the Phase 2 portion of the Phase 2/3 study has been completed and suspended until the results of Phase 2 are announced by NCI.
- A Phase 1/2 dose escalation study (NCT05146739) to explore safety and preliminary activity of uproleselan plus fludarabine and high dose cytarabine (FLA) in pediatric AML patients after 2 or more prior therapies.
Uproleselan is also being evaluated in several Investigator Initiated Trials (IIT’s):
- NCT04848974 — Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
- NCT05569512 — Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
- NCT04964505 — Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
- NCT05146739 — Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
Other Clinical Programs
To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov: a publicly and privately supported registry of clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidate’s name (e.g., uproleselan).